Placebo for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Oct 2020: Trial registered, NCT04599855
  2. 4 Nov 2020: Trial started, NCT04599855

The trials

NCT04599855: A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 4
People
477 taking part
Started
4 Nov 2020
Primary completion
31 Jan 2024
Arms
Placebo
Results
Posted on the registry
  1. 23 Oct 2020: Trial registered
  2. 4 Nov 2020: Trial started
  3. 31 Jan 2024: Trial completed
  4. 4 Mar 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.